Exchange: NYSE·Updated 07:58 PM EDT

MRK News

News
all
press releases
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.
Zacks
More News
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
Zacks
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Zacks
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.
Zacks
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
AstraZeneca's pipeline setbacks weigh on the stock, but blockbuster drugs, oncology growth and a strong launch pipeline offer reasons to stay invested.
Zacks
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Eli Lilly's 10th deal of 2026 expands its immunology pipeline, underscoring an aggressive push to build growth drivers beyond its blockbuster cardiometabolic franchise.
Zacks
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a...
Business Wire
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Zacks
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Zacks

Advertisement|Remove ads.